Sanofi has announced it will extend its partnership with technology company Medidata to expedite the development of new therapies. 

The new agreement will take advantage of the Medidata Patient, Data, and Study Experiences, building on both organisations’ aim to boost innovation in studies, speed new therapies to market, and promote health outcomes for people globally. 

The Medidata Experiences address the fragmented, standalone tools of the life sciences industry by offering AI-embedded, platform-based solutions across clinical workflows, unifying trial processes, diminishing silos, and reducing costs and delays. Combining these Experiences with Sanofi’s pharmaceutical knowledge will advance studies, amplifying the development of therapies with greater precision and impact. 

“Sanofi and Medidata have worked together for a decade within clinical research, including a collaboration in 2024,” said Gaelan Ritter, Global Head of Digital Clinical Development at Sanofi.  

“With this broadened relationship, we will continue harnessing the power of AI, optimising our clinical trials, and ultimately expediting the delivery of groundbreaking medicines.” 

Sanofi will employ Medidata’s expertise and capabilities in decentralised clinical trials as part of the new enterprise agreement. Medidata will also provide strategic consulting and end-to-end operational support, allowing Sanofi to further streamline research processes. 

“Clinical development is complex, and biopharma companies demand a strategic partner who can help them enhance data quality, improve study design, and elevate patient care,” said Lisa Moneymaker, Chief Strategy Officer at Medidata.  

“Through our alliance, Sanofi can leverage our unified solutions, specifically mapped out to meet their core needs, to simplify execution and accelerate the entire clinical development process.” 

Bruno Quinney, Content Team, DDW